STEPHEN A SHERWIN

CIK 1079462 · Chairman and CEO · last filed 2026-09-03

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.62M

Companies

9

Total Filings

106

Lifetime Open-Market Net

-$28.66M

Filer Profile

Reported Address
C/O NEUROCRINE BIOSCIENCES, INC.
6027 EDGEWOOD BEND COURT
SAN DIEGO, CA 92130
State of Incorporation
DE
Related Filers
NEUROCRINE BIOSCIENCES INC — 52 joint filings, latest 2026-09-03
BIOGEN INC. — 35 joint filings, latest 2026-06-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NBIX Director 14,860 $156.22 $2.32M -$18.51M 41 2026-09-03
BIIB Director 15,193 $217.15 $3.30M -$10.17M 30 2026-06-11
CHINOOK THERAPEUTICS, INC. (ADRO) Delisted Director $0 6 2020-05-28
Neon Therapeutics, Inc. (NTGN) Delisted Director 0 $0 2 2020-05-06
RIGL Director $47.24 $0 9 2016-05-12
VSTM Director 208 $7.32 $1.5K $21.4K 4 2015-06-16
Fresh Tracks Therapeutics, Inc. (VICL) Delisted Director 314 $70 2 2015-05-26
ANI PHARMACEUTICALS INC (BPAX) Delisted Director 15,374 $0 4 2012-03-30
CELL GENESYS INC (CEGE) Delisted Chairman and CEO 30,000 $0 4 2009-10-15

Recent Filings · Page 3 of 11

106 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-06-28 BIIB Grant (A) +960 $0 EDGAR
2023-05-19 NBIX Grant (A) $0 EDGAR
2023-01-05 NBIX Mixed -$3.18M EDGAR
2022-06-17 BIIB Grant (A) +1,370 $0 EDGAR
2022-05-20 NBIX Grant (A) $0 EDGAR
2022-01-26 NBIX Mixed -$1.02M EDGAR
2021-12-16 NBIX Gift (G) −2,000 $0 EDGAR
2021-07-02 BIIB Grant (A) +775 $0 EDGAR
2021-05-20 NBIX Grant (A) $0 EDGAR
2020-12-07 NBIX Gift (G) −2,806 $0 EDGAR
Showing 2130 of 106
Page 3 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.